Mark Stone began his tenure as CEO and President of the FSH Society in September.  Stone is a leading executive in health care-related non-profit organizations, having served as an executive leader of research-focused patient advocacy groups for the past 13 years, most recently as the CEO of NephCure Kidney International.  During his tenure at NephCure, Stone launched the NephCure Accelerating Cures Institute (NACI), a drug discovery initiative anchored by a clinical trial network comprising more than 35 sites, which seeks to expedite potential treatments for nephrotic syndrome.